EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023

Oct 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-10-16

Reporting Person: Elston George (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-10-16	Stock Option (Right to Buy)	$8.23	A	30000.00	Acquired	2033-10-15	Common Stock (30000.00)	Direct

Footnotes

F1: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remainig thirty-six months